small biotechs rarely ever have impeccable CEOs.
its ok to dream, but if you were to list out 100 small biotechs and look into their CEO history, you won't find many CEOs at all that impress you. one of the most common complaints from biotech investors is that their management team, and almost always the CEO specifically, isn't getting the job done and isn't forthcoming with shareholders.
its a bit of a catch-22. an impeccable CEO candidate will be able to gain employment in bigger, better companies and so smaller biotechs often hire the less impeccable candidates, and then have less than stellar leadership and have trouble moving forward, which makes them unattractive to impeccable candidates.
maybe they will convince kivlighn to take the job. kivlighn is not a proven CEO, but he has a lot more experience in a lot more areas than cyrus, and is a much more qualified candidate. kivlighn is the type of professional they are more likely to end up hiring, rather than a proven professional CEO.
cyrus lacked credentials and they can do better than that. but the other challenge is timing. a solid CEO candidate likely doesn't want to step into the middle of all the current challenges. its much more likely that a solid CEO would come on board AFTER the hold is officially removed and AFTER some sort of reliable funding mechanism is established - which would include a successful private placement following a significant move in the share price (share price of 50 cents or above)
its ok to dream, and the CEO hiring process might end up being a big success, but it might still take a while, particularly if they are patient enough to wait for a very good candidate to emerge.
its ok to dream, but if you were to list out 100 small biotechs and look into their CEO history, you won't find many CEOs at all that impress you. one of the most common complaints from biotech investors is that their management team, and almost always the CEO specifically, isn't getting the job done and isn't forthcoming with shareholders.
its a bit of a catch-22. an impeccable CEO candidate will be able to gain employment in bigger, better companies and so smaller biotechs often hire the less impeccable candidates, and then have less than stellar leadership and have trouble moving forward, which makes them unattractive to impeccable candidates.
maybe they will convince kivlighn to take the job. kivlighn is not a proven CEO, but he has a lot more experience in a lot more areas than cyrus, and is a much more qualified candidate. kivlighn is the type of professional they are more likely to end up hiring, rather than a proven professional CEO.
cyrus lacked credentials and they can do better than that. but the other challenge is timing. a solid CEO candidate likely doesn't want to step into the middle of all the current challenges. its much more likely that a solid CEO would come on board AFTER the hold is officially removed and AFTER some sort of reliable funding mechanism is established - which would include a successful private placement following a significant move in the share price (share price of 50 cents or above)
its ok to dream, and the CEO hiring process might end up being a big success, but it might still take a while, particularly if they are patient enough to wait for a very good candidate to emerge.
4
